Three-year monitoring of serum p53 antibody during chemotherapy and surgery for stage IV rectal cancer

The overexpression of mutant p53 stimulates serum p53 antibody production in patients with colorectal carcinoma even in superficial tumors. Although the short-term perioperative monitoring of serum p53 antibody titers is reported to be useful in predicting tumor recurrence and patient survival in colorectal carcinoma, the clinical utility of the long-term monitoring of serum p53 antibody titers in patients with colorectal cancer remains unknown. Here, we report the 3-year monitoring of serum p53 antibody titers in a 60-year-old man with rectal cancer, clinical stage IV (T2N2M1b, lung and liver metastases), who was treated with chemotherapy and surgery. Screening tests for CEA (29.4 ng/ml), CA19-9 (41.1 U/ml), and serum p53 antibody (2170 U/ml) were positive before treatment. After chemotherapy with mFOLFOX6 + bevacizumab (B-mab), CEA and CA19-9 decreased to the normal range. However, serum p53 antibody titer remained positive (283 U/ml). After low anterior resection, the serum p53 antibody titer still remained positive (63.4 U/ml). Serum p53 antibody titer significantly changed and was associated with treatment response and tumor recurrence. In the last 6 months of the patient’s life, serum p53 antibody titer gradually decreased, which possibly reflects the modification of the patient’s immune response to p53 antigens.     

术前血清CEA、CA19-9、CA50联合检测在结直肠癌肝转移预测中的应用

目的研究术前血清CEA、CA19-9、CA50联合检测在结直肠癌肝转移预测中的应用价值。 方法选择2015年1月至2017年1月在中国医学科学院肿瘤医院接受手术治疗的结直肠癌患者316例为研究对象,其中结直肠癌伴有肝转移的患者158例作为实验组,并按照性别、年龄等匹配结直肠癌不伴有肝转移的患者158例作为对照组。对所有患者的术前血清癌胚抗原（CEA）、糖类抗原19-9（CA19-9）以及糖类抗原50（CA50）进行检测,采用单因素及多因素分析以上肿瘤标志物单独或联合检测在结直肠癌肝转移中的预测价值。 结果单因素及多因素分析结果表明,术前血清CEA、CA19-9、CA50升高与结直肠癌发生肝转移显著相关（P<0.05）,CEA、CA19-9、CA50单独预测结直肠癌肝转移的敏感度分别为62.7%、57.4%、67.1%;特异度分别为58.2%、53.5%、56.6%。CEA、CA19-9、CA50联合诊断预测直肠癌肝转移的敏感度和特异度分别为74.3%、76.3%。 结论术前血清CEA、CA19-9、CA50升高是结直肠癌肝转移的独立预测因素,但三者单独预测结直肠癌肝转移的敏感度和特异度均较低。三者联合检测对于预测结直肠癌肝转移的敏感度和特异度均较高,可以作为结直肠癌肝转移的预测模型。     

结直肠癌患者血清MIC-1的表达及意义

目的评价结直肠癌患者血清中巨噬细胞抑制因子1（MIC-1）的表达水平及其临床意义。方法测定152例未经放化疗结直肠癌患者及120例健康对照组的血清MIC-1、癌胚抗原（CEA）及糖链抗原19—9（CA19—9）zk平。结果结直肠癌患者血清MIC-1水平较健康对照组显著升高（P〈0．01），MIC-1水平与Dukes分期、分化程度、浸润深度、淋巴转移、远处转移相关（P〈0．01），与年龄、组织类型无关。MIC-1表达与CEA呈正相关（r=0．514；P〈0．01），联合CEA及CA19-9检测可提高结直肠癌诊断的敏感性和准确率。结论血清MIC-1联合CEA及CA19-9对结直肠癌诊断和鉴别诊断有一定的临床应用价值。     

结直肠癌患者根治术前血清CEA和CA19-9表达水平对预后的预测价值

目的探讨结直肠癌患者根治术前CEA、CA19-9水平对预后的预测价值。 方法回顾性分析复旦大学附属肿瘤医院2003年12月至2007年1月间491例接受根治性切除的Ⅱ、Ⅲ期结直肠癌患者临床资料,包括患者术前血清CEA和CA19-9水平、临床病理资料及预后情况。利用单变量和多变量分析患者年龄、性别、肿瘤部位、肿瘤分化、TNM分期、肿瘤侵犯深度及淋巴结转移个数与预后的关系。 结果患者术前血清CEA和CA19-9水平、TNM分期、淋巴结转移数、肿瘤侵犯深度、肿瘤的分化都与预后相关。在多变量分析中,CEA和CA19-9水平、TNM分期、肿瘤分化是总生存的独立预测因素,CA19-9水平、TNM分期、肿瘤分化是无病生存的独立预测因素。 结论术前血清CA19-9与CEA水平均对结直肠癌患者的预后有预测价值。CA19-9水平应该作为常规的术前检查指标,对CEA检测结果有补充作用。     

Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer.

BACKGROUND/AIMS: Sialyl Le(x) (NeuAca2-3Galb1-4(Fuca1-3)GlcNAc1-R) (SLX) was introduced as cancer-associated. In this study, serological expression of SLX was examined with that of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9) and sialyl Tn antigen (STn) concerning the prognosis and clinicopathological findings of patients with colorectal carcinoma. METHODOLOGY: One hundred and seventeen patients were operated on for colorectal cancer and were enrolled in this study. Serum CEA, CA 19-9, STn and SLX levels were measured pre-operatively by radioimmunoassays and the cut-off values were 5ng/ml, 37U/ml, 45U/ml, and 38U/ml, respectively. RESULTS: Serologically, the positive rates of CEA, CA 19-9, STn and SLX antigens were 33.3, 26.5, 23.1, and 17.1%, respectively. The CEA, CA 19-9 and SLX are stage specific in clinical stage. In the CEA, CA 19-9, STn, SLX-positive patients, 5-year survival rates were 41.0, 29.7, 50.1, and 29.1%, respectively. In the tumor marker-positive patients, prognosis was significantly poorer than in the negative patients. In the patients with Curability A or B, the difference in survival between the SLX-positive and negative patients was significant. Multivariate analysis revealed that significant prognostic indicators were accompanying liver metastasis, histological type, depth of invasion, CEA and SLX. CONCLUSIONS: The combination assay of serum CEA, CA 19-9, STn and SLX will be beneficial for diagnosis and follow-up of colorectal cancer.     

Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer

Although serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 are commonly measured before surgery for gastric carcinoma, this clinical significance is not fully understood. We evaluated a total of 549 patients with gastric cancer who underwent gastrectomy. Levels of CEA and CA19-9 were measured preoperatively in all patients. We retrospectively analyzed correlations between CEA or CA19-9 and clinicopathologic features, and estimated the prognostic utility of the tumor markers by analyzing clinicopathologic characteristics of the carcinoma as a function of seropositivity or negativity of the antigens in combination or by raising the levels. The positivity rates of CEA (> or =5 ng/mL) and CA19-9 (> or =37 U/mL) were 19.5% and 18%, respectively. Serum CEA and CA19-9 positivity significantly correlated with depth of invasion, hepatic metastasis, and curativity. Forty-nine patients positive for both CEA and CA19-9 had significantly higher frequencies of lymph node metastasis, deeper invasion by the tumor, lower rates of curative resection (p < 0.01), and higher rates of hepatic metastasis (p < 0.05) than 377 patients with normal levels of CEA and CA19-9. Surgical outcomes of patients who were CEA- and CA19-9-positive were poorer than those of patients with normal CEA and CA19-9 levels (p < 0.01). Significant correlation was found between serum CEA and CA19-9 level (p < 0.001, r = 0.24). Doubling the threshold level of serum positivity to 10 ng/mL (CEA) and 74 U/mL (CA19-9) improved the prognostic value of these factors. However, multivariate analysis using Cox's hazards model revealed that only CEA positivity using the doubled threshold value (10 ng/mL) (p = 0.04, hazard ratio = 1.7), nodal involvement (p = 0.01, hazard ratio = 1.9), and depth of invasion (p = 0.02 hazard ratio = 1.5) significantly predicted prognosis. Carcinoembryonic antigen positivity using the doubled threshold level (10 ng/mL) was an important prognostic factor in patients with gastric cancer.     

The use of tumor markers as predictors of prognosis in gastric cancer

BACKGROUND/AIMS: The aim of this study was to evaluate the prognostic significance of serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA19-9) levels in patients with gastric cancer. METHODOLOGY: During the period January 2000 and January 2003, 36 patients operated for primary gastric cancer, at Sisli Etfal Training and Research Hospital, Department of General Surgery, were analyzed. Serum CEA and CA19-9 levels were determined preoperatively and the correlation between the elevated levels of tumor markers and several clinicopathological features, and survival were evaluated. RESULTS: Elevated serum CEA and CA19-9 levels were determined in 10 of 35 patients (28.6%), and 9 of 31 patients (29%), respectively, and both markers were elevated in 3 of 31 patients (9.6%). Elevated levels of CEA correlated with depth of invasion (p=0.018) and pathological stage (p=0.029); elevated levels of CA19-9 correlated with lymph node metastasis (p=0.026); and elevated levels of both markers correlated well with lymph node metastasis (p=0.031). The survival of patients with normal CEA levels was significantly better than those with elevated levels (p=0.0072). CONCLUSIONS: Preoperative serum CEA and CA19-9 levels may add useful information in patients with gastric carcinoma, and CEA level is a predictor of prognosis.     

肿瘤标记物结合病理对结直肠癌腹膜转移预判的研究

目的探讨血清CEA、CA19-9、CA125结合临床病理对术前判断是否具有结直肠癌腹膜转移的意义。 方法选取2014年1月至2017年10月在哈尔滨医科大学附属第二临床医学院行手术治疗的结肠癌及肿瘤位于直肠腹膜反折以上的直肠癌患者,共1 215例。其中,无腹膜转移的患者988例,同时性腹膜转移的患者227例,比较两组临床资料。 结果高分化腺癌、中分化腺癌、低分化腺癌、黏液腺癌、印戒细胞癌发生腹膜转移的几率分别为0、5.4%、35.6%、45.3%、75%,病理恶性程度越高越容易出现腹膜转移。血清CEA、CA19-9及CA125三者对结直肠癌腹膜转移的辅助诊断中,以CA125最为敏感,敏感度为100%,曲线下面积为0.897,CA125的这两项明显高于CEA及CA19-9,其特异度与CEA接近,较CA19-9低。CA19-9的特异度最高,为86%,但其灵敏度（47%）、曲线下面积（0.669）为三者中最低。CEA、CA19-9、CA125增高越明显,发生腹膜转移的几率就越大,当CEA＋CA125增高或CA125＋CA19-9增高或CEA＋CA125＋CA19-9增高时,发生腹膜转移的几率分别为65.7%、73.1%、77.3%。 结论通过CEA、CA19-9、CA125结合临床病理等检查的辅助,可以提高术前诊断结直肠癌腹膜转移的准确率,有助于术前判断患者的病情及预后。     

Elevated plasma gastrin,CEA, and CA 19-9 levels decrease after colorectal cancer resection

BACKGROUND AND AIMS: Gastrin stimulates mucosal growth of much of the gastrointestinal tract and has also been implicated in promoting growth of colonic tumors, but its role in colorectal carcinogenesis remains controversial. This study determined fasting serum gastrin levels before and after surgery for colorectal cancer (CRC) and the relationship to the clinical stage of the disease to investigate it possible prognostic role. PATIENTS AND METHODS: Fasting radioimmunoassay gastrin, CA 19-9, and CEA levels were measured before and after surgery for CRC. Helicobacter pylori status was also assessed since it causes significant hypergastrinemia. RESULTS: Mean fasting plasma gastrin level was significantly higher in CRC patients than in controls before surgery but not 59 days after surgery. Mean CEA and CA 19-9 levels were significantly higher in patients with CRC before surgery than after tumor resection. There was a significant positive correlation between the plasma gastrin, CEA, and CA 19-9 levels and the CRC stage (Dukes' classification). CONCLUSION: The significance of gastrin as a marker for diagnosis or prognostic purposes in colorectal cancer needs to be further examined.     

CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer

BACKGROUND/AIMS: Colorectal cancer is the third leading cause of cancer-related mortality in Taiwan. We became interested in searching for the factors predictive of survival. Serum CA19-9 (carbohydrate antigen 19-9) level has been reported as a factor predictive of survival in patients with colorectal cancer. A few articles have reported that patients with metastatic colorectal cancer who have normal (< or = 37 U/mL) serum CA19-9 levels survived significantly longer than those with higher serum CA19-9 levels. However, these reports are contradictory and lack definite conclusions. This study was carried out in an effort to evaluate the prognostic significance of serum CA19-9 levels in patients with metastatic colorectal cancer in Taiwan. METHODOLOGY: Between 1991 and 1994, a total of 128 patients with histologically confirmed metastatic colorectal cancers were evaluated retrospectively at Veterans General Hospital-Taipei. All patients had measurable metastatic lesions and life expectancies of more than 3 months. 5-Fluorouracil-based chemotherapy, either in a weekly bolus regimen or a monthly 5-day bolus schedule, were administered to all of them. Data on age, sex, performance status, location of primary tumor, extent of metastases, site of metastases, histological differentiation, serum CEA (carcinoembryonic antigen) and CA19-9 levels were analyzed before chemotherapy to determine their association with survival. Blood samples for CEA and CA19-9 measurement were analyzed using the radioimmunoassay method. Multivariate analysis by the Cox's proportional hazards regression model was performed to determine independent prognostic factors among all of the possible variables. RESULTS: By univariate analysis, serum CA19-9 levels (P < 0.001) and performance status of the patients (P = 0.022) were identified as prognostic factors, while age, sex, location of primary tumor, site of metastasis, histological differentiation, and pre-treatment serum CEA levels were not considered significant. By multivariate analysis, serum CA19-9 levels (P < 0.001) and performance status of the patients (P = 0.014) were still found as independent prognostic factors of these patients. CONCLUSIONS: The data from our study indicate that serum CA19-9 level is the most significant prognostic indicator of patients with metastatic colorectal cancer. It is recommended that stratification for further clinical trials for patients with metastatic colorectal cancer should be carried out according to serum CA19-9 levels.     

Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma

BACKGROUND/AIMS: Alteration of p53 gene links to the appearance and detection of anti-p53 antibodies in the serum. The aim of this study is to find the clinicopathologic significance for serum presence of anti-p53 antibodies in patients with colorectal carcinoma. METHODOLOGY: Serum presence of anti-p53 antibodies was examined for sera of 36 patients with colorectal carcinoma using enzyme-linked immunosorbent assay. RESULTS: Frequency of serum presence of anti-p53 antibodies was 47.2% (17 of 36). Incidence of lymph node metastasis and lymphatic invasion in tumors coexisting with serum presence of anti-p53 antibodies (70.6%, 12 of 17 and 94.1%, 16 of 17) were significantly higher than those in tumors without serum presence of anti-p53 antibodies (17.6%, 3 of 17 and 68.4%, 13 of 19; p = 0.007 and p = 0.041, respectively). Stages of the tumors were significantly more advanced in carcinomas coexisting with serum presence of anti-p53 antibodies (p = 0.023). Frequency in serum presence of anti-p53 antibodies among patients with tumors expressing p53 (73.7%, 14 of 19) was significantly higher than that among patients with tumors without p53 expression (17.6%, 3 of 17; p = 0.0005). CONCLUSIONS: Preoperative serum appearance of anti-53 antibodies can be an indicator for more malignant potential of colorectal carcinoma.     

p53 protein accumulation as a prognostic marker in sporadic colorectal cancer

Background and aims p53 protein plays a crucial role in the pathogenesis of a large number of malignancies. In this study, our goal was to elucidate the prognostic role of p53 overexpression and its relationship to clinicopathological variables in colorectal cancer. Materials and methods Between 1999 and 2004, surgical specimens of 258 patients who received surgical treatment for colorectal cancer at the Veterans General Hospital, Taipei were collected. p53 expression in tumor tissue was evaluated by immunohistochemical analysis using the human p53-specific mouse monoclonal antibody, PAb 1801. Results Of the 258 patients, 97 (37.6%) had overexpression of p53 in tumor tissues. The accumulation of p53 protein in tumor tissues did not correlate with age, gender, preoperative serum carcinoembryonic antigen (CEA) level, mucin content, nodal status, and tumor stage. A statistically significant correlation was found between p53 overexpression and location of the tumor in the rectum (p=0.038). Well to moderately differentiated tumors had significantly higher frequency of p53 overexpression than poorly differentiated tumors (40.0 vs 20.0%, p=0.050). Each patient was followed up for a minimum of 2 years (median 35 months). In univariate analysis, 3-year cancer-specific survival rate was significantly higher in patients with tumor p53 overexpression (88.2%) than in patients without overexpression (log rank test, p=0.037). However, in multivariate analysis, the tumour node metastasis stage remained the most significant independent prognostic factor. Conclusion The accumulation of p53 protein might have a favorable prognostic value in colorectal cancer, but it is not an independent prognostic factor.     

Prognostic factors following liver resection for hepatic metastases from colorectal cancer

AIM: To determine the impact of prognostic factors on survival of patients with metastases from colorectal cancer that underwent liver resection. METHODS: The records of 28 patients that underwent liver resection for metastases from colorectal cancer between April 1992 and September 2001 were retrospectively analyzed. Thirty-eight resections were performed (more than one resection in eight patients and two patients underwent re-resections). The primary tumor was resected in all the patients. A screening protocol for liver metastases including clinical examinations every three months, ultrassonography and CEA level until 5 years of follow-up and after every 6 months, was applied. The prognostic factors analyzed regarding the impact on survival were: Dukes C stage of primary tumor, size of metastasis >5 cm, a disease-free interval from primary tumor to metastasis < 1 year, CEA level > 100 ng/mL, resection margins < 1 cm and extrahepatic disease. The Kaplan-Meier curves, log rank and Cox regression were used for the statistical analysis. RESULTS: Perioperative morbidity and mortality were 39.3% and 3.6%, respectively. The 5-year survival rate was 35%. The independent prognostic factors were: disease-free interval from primary tumor to metastasis < 1 year and extrahepatic disease. CONCLUSIONS: The liver resection for metastases from colorectal cancer is a safe procedure with more than 30% 5-year survival. Disease-free interval from primary tumor to metastasis < 1 year and extrahepatic disease were independent prognostic factors.     

肿瘤标志物CEA、CA19-9在人结直肠癌检测中价值

目的探讨应用肿瘤标志物进行结直肠癌检测及预后判断的临床应用价值。方法汇总本院近3年收治的经手术治疗的结直肠癌患者191例,结合血清及组织学CEA、CA19-9的结果进行分析。结果归为DukeA期的患者仅占全部病例的12.57%。组织病理切片检查CEA、CA19-9阳性率分别为98.40%、74.24%;血清CEA、CA19-9阳性率分别为51.47%和22.39%;两项指标阳性率组织病理切片明显高于血清,P〈0.05,但其浓度与Duke分期具有正相关性。结论血清CEA、CA19-9测定对结直肠癌患者的诊断预后有临床应用价值,但对早期结直肠癌的筛查效果并不理想。     

结直肠癌患者血癌胚抗原mRNA检测的临床意义

背景:结直肠癌预后不佳,进一步研究结直肠癌患者肿瘤标记物的表达及其与肿瘤临床病理特征的关系对指导临床治疗具有重要意义.目的:检测结直肠癌患者的外周血癌胚抗原(CEA)、CEA mRNA以及肿瘤回流静脉血CEAmRNA,探讨血CEA mRNA检测在结直肠癌诊治中的临床意义.方法:以酶联免疫吸附测定(ELISA)检测71例结直肠癌患者的外周血清CEA,同时以巢式逆转录聚合酶链反应(RT-PCR)检测其外周血(71例)和肠系膜上静脉血(35例)CEA mRNA.分析血CEA和CEA mRNA的表达与结直肠癌临床病理特征的关系.结果:结直肠癌患者的外周血CEA mRNA阳性率为69.0%,显著低于肠系膜上静脉血的82.9%(P<0.05),外周血CEA阳性率(45.1%)显著低于CEA mRNA阳性率(P<0.01).Dukes C期和D期结直肠癌患者的外周血CEA和CEA mRNA阳性率显著高于A期和B期患者(P<0.05).Dukes D期肝转移患者肠系膜上静脉血CEA mRNA阳性率为85.7%(6/7).结论:检测外周血CEA mRNA有助于结直肠癌患者的预后判断,肿瘤回流静脉血CEA mRNA的检测对结直肠癌肝转移的诊断具有重要意义.     

Sialyl Tn antigen expression is associated with the prognosis of patients with advanced colorectal cancer

BACKGROUND/AIMS: One of the main problems in multimodal cancer treatment is the lack of prognostic parameters for the individual patient. This study was conducted to clarify the prognostic factors in patients with advanced colorectal cancer. METHODOLOGY: We examined DNA ploidy, Ki-67-derived growth fraction and the expression of CA 19-9, Sialyl Tn (STN) and carcinoembryonic antigens (CEA), along with standard clinicopathological variables including age, sex, tumor location, tumor size, cell differentiation, depth of invasion, and lymph node metastasis in 78 patients with advanced colorectal carcinoma, who underwent curative surgical resection. In addition, we determined the prognostic significance of these parameters. RESULTS: Forty-six patients (59.0%) showed aneuploidy and 32 (41.0%) showed diploidy. The Ki-67 labeling index ranged from 13.9-40.3% with a mean of 24.9%. The index was not correlated with standard clinicopathological variables. There was no significant correlation between seropositive rates for CEA, CA 19-9, or STN and standard clinicopathological variables except for age. In tumor tissue, the positive rates for these antigens were 62.8% for CA 19-9, 67.1% for STN, and 96.2% for CEA. There was no significant correlation between positive rates and clinicopathological variables. The expression of STN in serum had the strongest association with survival, followed by lymph node metastasis and expression of STN in tissue. CONCLUSIONS: We conclude that not only lymph node metastasis but also STN expression are important prognostic factors in patients with advanced colorectal carcinoma who undergo curative surgical resection.     

Value of serum carbohydrate antigen 19-9 for predicting extrahepatic metastasis in patients with liver metastasis from colorectal carcinoma

BACKGROUND/AIMS: Serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are frequently elevated in patients with colorectal carcinoma. However, the predictive utility of these two markers has not been fully investigated in patients with liver metastasis. METHODOLOGY: We retrospectively analyzed data obtained from 90 hepatectomy or non-hepatectomy patients with liver metastases from colorectal carcinoma. We examined correlation between serum levels of CEA and CA19-9 and other clinicopathologic factors and performed univariate and multivariate analyses to determine the impact of these tumor markers on extrahepatic metastasis after admission to our hospital. RESULTS: CEA elevation correlated to advanced age (> or = 60 years), and CA19-9 elevation correlated with the site (colon) of primary tumor. Univariate analysis showed that treatment without hepatectomy, > or = 4 hepatic tumors, and CA19-9 elevation had been an adverse effect on extrahepatic disease-free survival time after admission. Multivariate analysis showed that CA19-9 elevation (risk ratio, 1.84) and treatment without hepatectomy (risk ratio, 1.62) had a significant effect on extrahepatic disease-free time. CONCLUSIONS: In patients with colorectal liver metastasis, elevation of serum CA19-9 is a risk factor for extrahepatic metastasis, and CEA appears to be useless for predicting extrahepatic metastasis in these patients.     

伴有肝转移的结直肠癌患者血清CEA、CA199的分析

目的探讨血清CEA、CA199在晚期结直肠癌中的分布及与临床特征的关系。 方法将275例CRC患者分别按性别、年龄、肝转移、腹水、肠瘤直径、肠瘤位置、血便、乙肝进行分组,总结分析患者血清CEA、CA199的浓度均值、阳性率及与临床特征的关系。 结果伴肝转移,肿瘤位于结肠,有血便,有腹水的CRC患者中血清CEA、CA199的浓度均值均明显升高,差异有统计学意义(P<0.05)。而血清CEA、CA199的水平与性别、年龄、肠瘤直径、乙肝无明显相关性(P>0.05)。 结论血清CEA、CA199可作为早期诊断结直肠癌肝转移的一种有效方法,广泛的用于临床。     

结直肠癌患者血清CEA、CA19-9的检测价值

目的 探讨癌胚抗原（ＣＥＡ）、糖链抗原（ＣＡ１９－９）在结直肠癌的诊断、观察预后、监测复发转移中的应用价值。方法 ＣＥＡ采用ＥＬＩＳＡ法、ＣＡ１９－９采用放免法,对１９例结肠癌、２６例直肠癌、３０例正常人进行了分析,并在术后定期检查。ＣＥＡ、ＣＡ１９－９水平下降,可恢复至正常：术后复发ＣＥＡ、ＣＡ１９－９重又异常升高,伴广泛转移者升高更加显著,并且ＣＥＲＡ、ＣＡ１９－９的升高出现在临床症状和Ｘ线异